Applied Health Signals company Livongo Health, today announced the launch of the Study to Understand Gaining Access to Blood Glucose Records (SUGAR), or SUGAR study, a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF). The aim of the clinical trial is to measure the impact of the Livongo for Diabetes program compared to the average standard of care approach to diabetes management utilizing a traditional Bluetooth glucose meter.
SUGAR Study Background/Overview
The randomized controlled clinical trial will randomize 300 people with diabetes to either participate in the Livongo for Diabetes program, which includes a cellular-connected blood glucose meter, unlimited free test strips, remote digital and 1:1 coaching with Certified Diabetes Educators, or receive a Bluetooth glucose meter and unlimited free test strips.
HbA1c is a commonly accepted lab measure for average blood glucose levels over a 90-day period. The HbA1c level can be a marker of the effectiveness of a diabetes management solution. The final results of the study will compare hemoglobin A1c (HbA1c) changes in both populations at six months.
SUGAR Study Participants
SUGAR study participants include:
● People with a diagnosis of type 2 diabetes mellitus on any type of medication
● Adults, age 18 years or older
● People not using a continuous glucose monitoring device nor an insulin pump
● iPhone users with access to data and/or Wi-Fi
Livongo for Diabetes Program
The Livongo for Diabetes program is backed by a team of data scientists who Aggregate, Interpret, Apply and Iterate (AI+AI)™ substantial amounts of health data and information to create actionable, personalized and timely insights, information and nudges to improve how Livongo members experience their chronic condition. “We are interested to see how an innovative solution like Livongo truly impacts people,” said Jenise Wong, MD, Ph.D., Assistant Professor at UCSF and Principal Investigator of the SUGAR study. “By conducting a randomized controlled trial, we can better understand the degree to which innovative offerings improve health outcomes.”